Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Ventrus Biosciences, Inc. to Contact the Firm NEW YORK, July 3, 2013 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (Nasdaq:VTUS) of the Monday, July 8, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain executives. A complaint has been filed on behalf of all persons who purchased or otherwise acquired Ventrus common stock between December 17, 2010 and June 25, 2012 (the "Class Period"). The investigation focuses on whether the Company and its executives violated federal securities laws by issuing false and/or misleading statements and failing to disclose materially adverse facts concerning the Company's lead product iferanserin (VEN 309) ("VEN 309"). The Company described VEN 309 as a new chemical entity for the topical treatment of symptomatic internal hemorrhoids. According to Ventrus, VEN 309 demonstrated good tolerability and no severe adverse events while showing statistically significant improvements in bleeding, itchiness, and pain in seven clinical studies between 1993 and 2003. Moreover, the Company touted that the prior results from Phase II trials of VEN 309 demonstrated the product's clinical efficacy. However, Ventrus issued a press release on June 25, 2012 announcing that VEN 309 failed its Phase III trial, causing the Company to abandon further development of VEN 309, including any further attempt to obtain FDA approval. In response to this news, the price of Ventrus common stock plummeted over 50%, to $5.02 per share, on June 25, 2012. Request more information now by clicking here:www.faruqilaw.com/VTUS. There is no cost or obligation to you. Take Action If you invested in Ventrus stock or options between December 17, 2010 and June 25, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/VTUS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org or email@example.com.Faruqi & Faruqi, LLP also encourages anyone with information regarding Ventrus' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising.The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).Prior results do not guarantee or predict a similar outcome with respect to any future matter.We welcome the opportunity to discuss your particular case.All communications will be treated in a confidential manner. CONTACT: FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. firstname.lastname@example.org Francis McConville, Esq. email@example.com Telephone: (877) 247-4292 or (212) 983-9330
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Ventrus Biosciences, Inc. to
Press spacebar to pause and continue. Press esc to stop.